(Q37930463)

25 August 2017

1 reference

title

CETP Inhibition: does the future look promising? (English)

1 reference

25 August 2017

Peter P Toth

1

1 reference

25 August 2017

publication date

1 December 2011

1 reference

Current cardiology reports

25 August 2017

published in

1 reference

25 August 2017

volume

13

1 reference

25 August 2017

issue

6

1 reference

25 August 2017

page(s)

559-565

1 reference

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Activation of intracellular signaling systems by high-density lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Serum lipid concentrations and prevalence of dyslipidemia in a large professional population in Beijing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Pharmacomodulation of High-Density Lipoprotein Metabolism as a Therapeutic Intervention for Atherosclerotic Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

The effect of cholesteryl ester transfer protein -629C->A promoter polymorphism on high-density lipoprotein cholesterol is dependent on serum triglycerides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Effect of torcetrapib on the progression of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosc

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Cholesteryl ester transfer protein antagonism by drugs--a poor choice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Aldosterone production in human adrenocortical cells is stimulated by high-density lipoprotein 2 (HDL2) through increased expression of aldosterone synthase (CYP11B2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Safety and tolerability of dalcetrapib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Safety of anacetrapib in patients with or at high risk for coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Biochemical characterization of cholesteryl ester transfer protein inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-011-0218-X

Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity

21 January 2018

1 reference

12 December 2020

Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: The Copenhagen City Heart Study

1 reference

12 December 2020

Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition

1 reference

12 December 2020

Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene

1 reference

12 December 2020

High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey.

1 reference

12 December 2020

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

1 reference

12 December 2020

Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study

1 reference

12 December 2020

10.1007/S11886-011-0218-X

Identifiers

DOI

1 reference

25 August 2017

1 reference